François‐Xavier Danlos
A5060675099- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Medical Imaging and Pathology Studies
- Pleural and Pulmonary Diseases
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- IgG4-Related and Inflammatory Diseases
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- vaccines and immunoinformatics approaches
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Sarcoidosis and Beryllium Toxicity Research
- Colorectal and Anal Carcinomas
- Cancer, Hypoxia, and Metabolism
Institut Gustave Roussy
2018-2025
Inserm
2017-2025
Dana-Farber Cancer Institute
2024-2025
Harvard University
2024-2025
Université Paris-Saclay
2018-2024
La Ligue Contre le Cancer
2022-2023
Institut Curie
2017-2021
Immunité et Cancer
2017-2018
Pitié-Salpêtrière Hospital
2017
Assistance Publique – Hôpitaux de Paris
2016-2017
Immune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune-related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy ICIs in disease cancer.A retrospective cohort conducted January 2017 2018 via 3 French national networks experts oncology autoimmunity. Adults who were receiving assessed occurrence flare disease, other IRAEs,...
Abstract The circulating metabolome provides a snapshot of the physiological state organism responding to pathogenic challenges. Here we report alterations in plasma reflecting clinical presentation COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), critical (in intensive care). This analysis revealed major disease- stage-associated shifts metabolome, meaning that at least 77 metabolites including...
Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1) blockade in cancer patients, but mechanisms underlying their immunosuppressive effects remain unknown. By inducing down-regulation mucosal addressin adhesion molecule (MAdCAM-1) ileum, post-ABX gut recolonization by Enterocloster species drove emigration enterotropic α4β7+CD4+ regulatory T 17 cells into tumor. These deleterious ABX were mimicked oral gavage species, genetic deficiency, or antibody-mediated...
Chemotherapy associated with Immune Checkpoint Inhibitors is currently the standard of care in several tumor indications. This combination approach improves progression free survival (PFS), overall (OS) and complete pathological response (pCR) cancer types both early metastatic approaches. However, distinct spectrum toxicities between cytotoxic side effects immune related adverse events (irAEs) similar clinical presentations different management strategies remains a challenge daily practice...
Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice patients inflammatory arthritis (IA) and history cancer. To perform systematic literature review to inform Task Force formulating EULAR points consider on the initiation targeted IA Specific research questions were defined within before exact queries librarian. We included studies reporting relative measure cancer initiating therapy or conventional synthetic...
<h3>Background</h3> Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients a PNS. Our objective was to describe the outcome for pre-existing newly diagnosed PNS following initiation of immunotherapy. <h3>Methods</h3> We included all adult (aged ≥18) treated solid tumor, PNS, and registered French pharmacovigilance databases. Patients were allocated cohorts 1 2 if had been before vs....
Abstract Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) among best therapeutic targets pembrolizumab correlating progression-free survival. TFH were associated tumoral CD8 PD-L1 expression at baseline induction tertiary lymphoid structures after pembrolizumab. Blood central memory accumulated in tumors...
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets patients and is now standard care several solid tumor types. However, immunotherapy activity beyond conventional immune checkpoint inhibition plateauing, biomarkers are overall lacking to guide treatment selection. Most studies have focused on T cell engagement response, but there a growing evidence that B cells may be key players establishment an organized notably through tertiary...
Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cell lines, freshly resected human tumors, samples from cohorts patients before BCG therapy, we demonstrate 2 distinct patterns immune subversion upon relapse. In the first pattern, intracellular infection cells induced...
PURPOSE High-risk clonal hematopoiesis (CH) is frequently incidentally found in patients with solid tumors undergoing plasma cell–free DNA sequencing. Here, we aimed to determine if the incidental detection of high-risk CH by liquid biopsy may reveal occult hematologic malignancies tumors. MATERIALS AND METHODS Adult advanced cancers enrolled Gustave Roussy Cancer Profiling study (ClinicalTrials.gov identifier: NCT04932525 ) underwent at least one (FoundationOne Liquid CDx). Molecular...
Programmed cell death protein-1 (PD-1) expression has been associated with activation and exhaustion of both the CD4 CD8 populations in advanced non-small lung cancer (aNSCLC). Nevertheless, impact balance between circulating CD8+PD-1+ CD4+PD-1+ patients treated immune checkpoint blockers (ICB) is unknown. The to ratio (PD-1-Expressing Ratio on Lymphocytes a Systemic blood sample, or 'PERLS') was determined by cytometry fresh whole from aNSCLC before treatment single-agent ICB targeting PD-1...
Abstract Background We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, anti-PD1 immunotherapy, patients advanced solid tumors (PEMBIB trial; NCT02856425). Methods In this monocentric phase Ib dose escalation cohort, we evaluated escalating doses nintedanib (Dose level 1 (DL1) = 150 mg bid [ bis die , as twice a day]; DL2 200 bid, delivery) pembrolizumab (200 Q3W, IV). Patients received 1-week...